Searching for "monogenic diabetes" in dogs using a candidate gene approach
© Short et al.; licensee BioMed Central Ltd. 2014
Received: 13 March 2014
Accepted: 23 June 2014
Published: 7 July 2014
Canine diabetes is a common endocrine disorder with an estimated breed-related prevalence ranging from 0.005% to 1.5% in pet dogs. Increased prevalence in some breeds suggests that diabetes in dogs is influenced by genetic factors and similarities between canine and human diabetes phenotypes suggest that the same genes might be associated with disease susceptibility in both species. Between 1-5% of human diabetes cases result from mutations in a single gene, including maturity onset diabetes of the adult (MODY) and neonatal diabetes mellitus (NDM). It is not clear whether monogenic forms of diabetes exist within some dog breeds. Identification of forms of canine monogenic diabetes could help to resolve the heterogeneity of the condition and lead to development of breed-specific genetic tests for diabetes susceptibility.
Seventeen dog breeds were screened for single nucleotide polymorphisms (SNPs) in eighteen genes that have been associated with human MODY/NDM. Six SNP associations were found from five genes, with one gene (ZFP57) being associated in two different breeds.
Some of the genes that have been associated with susceptibility to MODY and NDM in humans appear to also be associated with canine diabetes, although the limited number of associations identified in this study indicates canine diabetes is a heterogeneous condition and is most likely to be a polygenic trait in most dog breeds.
KeywordsDiabetes mellitus Dog breeds Candidate genes
Diabetes is a common condition where sugar (glucose) levels of the body are poorly regulated, due to either lack of production of the hormone insulin, made in the pancreas, or an increase in resistance of tissues in the body to the effects of insulin. Canine diabetes is similar to some forms of human diabetes; it is relatively common in dogs, and its prevalence (the proportion of dogs affected at a point in time) ranges from 0.005% to 1.5%, and is dependent on which breed is being considered. This breed-related variation in the prevalence of diabetes suggests a genetic basis in dogs.
In humans, some forms of diabetes are due to mutations in just a single gene (these are called monogenic conditions). This study examined 18 genes that are known to be associated with human monogenic diabetes, and tested whether they are also associated with diabetes in 17 different dog breeds.
Six variants from five genes were found to be associated with diabetes in some breeds. Interestingly, two different variants in the same gene (called ZFP57 - Zinc finger protein 57) were associated with diabetes in two different breeds.
Canine diabetes is a common endocrine disorder with an estimated prevalence ranging from 0.005% to 1.5% . Almost all diabetic dogs require exogenous insulin therapy to manage their hyperglycaemia, often resulting from insulin deficiency leading to the inability to control their blood glucose concentration. Canine diabetes has been compared with human type 1 diabetes (T1D) [2, 3] as they share many clinical and pathophysiological features. However, in contrast with T1D, which is usually diagnosed in young patients (<30 years of age), canine insulin-deficiency diabetes (IDD) occurs more commonly in older dogs, aged 7–12 years .
The aetiology and underlying pathogenesis of canine IDD has not been fully determined, although exocrine pancreatic disease [5, 6] and immune-mediated mechanisms  are suspected to be underlying causes of pancreatic beta cell destruction. It has been also been suggested that, in many ways, canine diabetes resembles latent autoimmune diabetes of the adult (LADA) in man , a more slowly progressive form of autoimmune diabetes.
Pedigree dog breeds, similar to some ethnic groups in the human population , display variability in diabetes susceptibility, with some breeds (e.g. Samoyed) being over-represented, whereas others (e.g. Boxer) seem to be relatively resistant to developing the disease . These breed-related differences in diabetes susceptibility suggest that the pathogenesis of diabetes is influenced by genetic factors and similarities between canine and human diabetes phenotypes indicate that the same genes and/or genetic pathways might be involved in both species. Since some phenotypes also appear to be somewhat breed-specific , for example NDM, in Keeshond dogs  and dioestrus diabetes in female entire Elkhounds and Lapphunds , there could be differences in the individual susceptibility genes that contribute to the overall genetic risk for different dog breeds, as is seen with different ethnic groups and type 2 diabetes in humans .
A small proportion of human diabetic patients suffer from disease resulting from mutation(s) in a single gene. These monogenic forms of diabetes account for around 1-5% of human diabetes cases and include maturity onset diabetes of the young (MODY) and neonatal diabetes mellitus (NDM) . MODY represents a heterogeneous group of disorders that are commonly diagnosed before 25 years of age in humans. They result from autosomal dominant mutations in genes that control the synthesis or secretion of insulin by the pancreatic beta cells and include HNF4A (MODY1) , GCK (MODY2) [17, 18], HNF1A (MODY3) [19, 20], PDX1 (MODY4)  and HNF1B (MODY5) . NDM is commonly diagnosed around 6 months of age in humans and can be the result of sporadic or inherited (autosomal dominant) mutations in certain genes, including KCNJ11, ABCC8 and insulin (INS) [23, 24]. Mutations in the glucokinase (GCK) gene can also lead to NDM .
Although the majority of diabetic dogs (>90%) are diagnosed in animals over 6 years of age , within the population of young diabetic dogs (diagnosed <6 years), there is a clear breed-related overrepresentation of Golden and Labrador Retrievers . Screening for mutations in canine KCNJ11 and INS have not so far identified any genetic anomalies in a cohort of dogs in the United Kingdom that were affected with NDM (Catchpole unpublished data). NDM has been reported in a small number of dog breeds in the USA , including an inherited form in Keeshonds, where the specific genetic defect was not identified, but which is believed to be inherited in an autosomal recessive manner .
While the domestication of the dog from the wolf is believed to have occurred some 15,000-200,000 years ago , most modern pedigree dog breeds have been created in the last 300 years and represent distinct, genetically segregated populations with high levels of inbreeding and reduced heterogeneity. The relatively short time frame taken to establish modern breeds has been insufficient for chromosomal restructuring to take place and as a result of this, they have extended linkage disequilibrium (LD) and long haplotype blocks within a breed . The selection bias for ‘desirable’ morphological and behavioural traits (hunting instinct, head shape etc.) that has been used to create modern breeds has resulted in a concentration of the gene(s) associated with the trait within a given breed. Inadvertently, disease-associated genes have also been concentrated alongside the morphological and behavioural traits, resulting in each breed demonstrating highly variable disease incidences for particular conditions [30, 31].
Identification of a monogenic type of diabetes in a particular dog breed could lead to the development of a breed-specific genetic test for diabetes susceptibility.
To date, the genes that have been identified as causing monogenic types of diabetes in humans have not been evaluated in the diabetic dog population, where it is possible that some breeds may express a monogenic form of the condition. The aim of the present study was to screen single nucleotide polymorphisms (SNPs) from eighteen genes that have been associated with human MODY/NDM in seventeen dog breeds in order to resolve, at least in part, canine diabetes breed-related genetic susceptibilities. Although samples sizes were relatively small for some breeds examined it has been recognised that only 20–50 affected dogs are usually required for identifying conditions with a monogenic aetiology .
Breeds used in the study and overview of SNP analysis
Cavalier King Charles Spaniel
Jack Russell terrier
Staffordshire Bull terrier
West Highland White terrier
Of the associated SNPs, three were intronic (rs24305581, rs22302353, rs23892119) and three were synonymous coding SNPs, (rs23901704, rs22686871 rs8804236, Table 2).
Three SNPs were associated with diabetes in the Cocker Spaniel breed (Table 2). For SNPs rs22302353 and rs22686871, the major allele homozygote (GG and TT respectively) was more common in the cases than the controls and for rs22686871, it represented 100% of the case genotypes, compared to 78.5% of the controls (Figure 1). For SNP rs24305581, the minor allele (‘A’) was found in 69.7% of the case genotypes (AA+AG) vs. 39.4% of the control genotypes and the GG genotype was more common in the controls (60.6%) than the cases (29.3%, Figure 1). The heterozygous genotype for this SNP represented more than 50% of the case genotypes but only 33.3% of the control genotypes. Analysis of genotype combinations across these three associated markers in this breed did not identify any genotype combinations that were more or less common in either the case or the control populations, indicating that the associations are independent of each other (data not shown).
Some cases of canine diabetes share several similarities with the monogenic forms of human diabetes, known as maturity onset diabetes of the young (MODY). To date, however, there is no reported evidence of monogenic diabetes association studies in dogs. We identified six canine allelic associations to genes that are causative for human monogenic forms of diabetes, but none of these associations can fully explain diabetes risk in any given dog breed. One gene (ZFP57) was associated with two different SNPs in two disparate breeds (Bichon Frise and Samoyed) and one breed (Cocker Spaniel) had an association with three SNPs from three different genes (MTTL1, PAX4, INS). The allele and genotype frequencies do not indicate that these associations explain the full susceptibility to canine breed-related diabetes and suggest that canine diabetes is a polygenic trait with multiple genes conferring susceptibility. They could suggest, however, that a proportion of the dogs within a breed have a monogenic form of diabetes and that the remainder of the breed have a polygenic form of the condition. This requires further investigation for better clarification.
Associations within the Cocker Spaniel breed could suggest that three types of monogenic diabetes co-exist within this breed if, for example, they were in LD with the causative SNP rather than being the actual causative SNP. This seems highly unlikely however, given the reported genetic uniformity of pedigree dog breeds, although genome-wide analysis (GWA) of Cocker Spaniels within our overall sample population has identified three distinct clusters of Cocker Spaniels when viewed on a multi-dimensional scaling plot (Jonathan Massey, unpublished data). The representation of three clusters following GWA indicates the presence of genetic stratification within the breed and could explain, in part, the association of three different genes, each representing a distinct type of diabetes within this breed in which the respective genes are contributory to diabetes susceptibility within a cluster but that other unidentified genes are also contributory. The lack of GWA data on the specific dogs used in this candidate gene study prevents the stratification of this cohort into genome-wide sub-populations but could be a useful investigation strategy for future studies.
Three of the associated SNPs were intronic (rs24305581, rs22302353, rs23892119, Table 2) and while the specific function of these SNPs is unknown at the current time, intronic SNPs are known to affect gene expression through regulatory elements and have been shown to activate cryptic splice sites, leading to alternative splicing .
The other three associated SNPs were synonymous coding SNPs (rs23901704, rs22686871 rs8804236, Table 2) and it is well documented that synonymous SNPs affect gene function through mRNA splicing and can also affect precursor mRNA splicing, RNA stability and structure and protein folding. These synonymous SNPs could, therefore, result in ectopic mRNA splice sites and generate null, antagonising or agonistic protein isoforms leading to the diabetic disease phenotype. They could equally affect mRNA stability and subsequently the amount of available protein transcript could be increased or decreased or they could result in defective protein that do not function properly.
The majority of breeds used in this analysis were not associated with the candidate genes that were selected. A monogenic type of diabetes could still exist within these breeds, but as yet the causative gene has not yet been identified. Alternatively it could be that the canine version of the causative gene was insufficiently annotated at the time of study and thus not included in the present study. An example of the latter is glucokinase which would be a good candidate gene, once the canine GCK sequence (XM_846042.2) and its chromosomal location have been better resolved (CanFam 3.1, http://www.ncbi.nlm.nih.gov/gene/606490).
The limited number of associations with monogenic diabetes susceptibility genes could also indicate that canine diabetes is largely polygenic in most breeds and could also be subject to environmental influences. The finding of a small number of significant gene associations, and even some of the associations not retained following statistical correction, may indicate that these genes represent small risk contributions to a larger undiscovered polygenetic aetiology. This is further supported by the allele frequencies of the non-associated breeds in the study which are provided as additional information (Additional file 1: Table S1) and show that the associated alleles are often present in the other breeds but do not reach significance. In some breeds, the allele that is associated with diabetes in one breed is found at equal frequency in cases and controls of a different breed. For example, SNP rs23901704 showed an association to diabetes in the Samoyed (Table 2) with the minor allele (C) being found at a frequency of 0.11 in the cases only. This same allele (C) was found at similar frequencies for both controls and cases respectively in the Border collie (0.2 and 0.17), Labrador (0.17 vs. 0.22), Miniature schnauzer (0.36 vs. 0.34), Samoyed (0.15 vs. 0.17) Springer Spaniel (0.08 vs. 0.12), West Highland white terrier (0.16 vs. 0.18) and Yorkshire terrier (0.09 vs. 0.06). Similar trends are seen for the other associated SNPs in the different breeds.
A number of immunity-related genes, including the dog leukocyte antigen (DLA) have already been associated with canine diabetes in some breeds [57–61]. This is not surprising, however, given the pathogenesis of the condition and the potential immune-mediated destruction of pancreatic beta cells. Many of the cytokine SNPs that have been associated with an increased risk of developing canine diabetes are from the Th2 subset [57–60]. This is important because the Th1-Th2 balance is considered to be instrumental in the development of this condition and diabetes is believed to be initiated by Th1 cytokines.
To achieve significant power in genome-wide association studies (GWAS) to identify genes and estimate the size of their contribution in complex polygenic conditions, human genetic analysis cohorts often require thousands of cases and controls. This is not the case in GWAS studies of pedigree dog breeds where the sample size may be as few as a hundred and power is increased when taking into account the small number of founder members for a given breed, the high level of inbreeding and the extended linkage disequilibrium and haplotype structure that exists in pedigree dog breeds . It has been suggested that even fewer cases and an equal number of controls are sufficient to detect the disease allele for a simple Mendelian recessive trait . With the exception of the Staffordshire bull terrier and Doberman, all of our breed cohorts contained more than 20 cases and controls, suggesting we should have had sufficient statistical power to detect associations for a monogenic disorder. The limited number of associations identified in this study is therefore most likely to be due to canine diabetes being a polygenic trait in most dog breeds.
This is the first multi-breed candidate gene analysis to investigate gene homologues in the dog that are equivalent to human monogenic forms of diabetes. We have evidence that some of the same genes that have been associated with susceptibility to MODY and NDM in humans are also associated with canine diabetes, although the number of breeds where this applies is limited and it is more likely that canine diabetes is a polygenic trait. Recruitment of cases or controls to such studies is difficult unless performed under a Home Office animal licence and most veterinary blood samples submitted to laboratories for DNA isolation are generally residual from other diagnostic tests.
The underlying aetiology and pathogenesis of canine diabetes have not been fully established and while insulin deficiency is a consistent feature, it remains a heterogeneous condition. The presence of specific breed predispositions and phenotypes within breeds suggests an underlying genetic basis for diabetes susceptibility but this susceptibility varies between breeds and is likely to result from the interactions of multiple genes. The current study and previous candidate gene studies have identified breed-specific genetic associations with the condition, but none of the identified associations can fully explain canine diabetes susceptibility. Ongoing GWA studies are expected to identify new loci that will further explain the breed susceptibility to diabetes in dogs.
Blood samples from diabetic dogs were selected from the UK Canine Diabetes Register and Archive (Royal Veterinary College, University of London). Diagnosis of diabetes was based on consistent clinical signs (polyuria, polydipsia and weight loss) and documented hyperglycaemia (i.e. > 9 mmol/l) with glucosuria. Entire females were excluded from the study to eliminate dogs suffering from dioestrus diabetes, an insulin-resistance form of the disease. Dog samples representing seventeen breeds were selected from a larger collection of diabetic samples on the basis of providing a sample size n ≥ 15 in each breed group (Table 1). Breed-matched, control samples (without diabetes) were selected from a large archive of DNA samples ( http://www.liv.ac.uk/dna_archive_for_companion_animals/) UK DNA Archive for Companion Animals, Universities of Manchester and Liverpool) which collects samples from animals being treated for a range of conditions. For this cohort, controls were selected as samples from dogs that were older than 7 years of age and had been diagnosed with (and were responding to treatment for) non-autoimmune, non-endocrine conditions. Conditions permitted for inclusion were those where the clinical signs were least likely to present with a diabetic phenotype and included, but was not limited to, hip dysplasia, cruciate rupture and neurological dysfunction (epilepsy). It was not possible to test for hyperglycaemia in these retrospectively recruited samples. Control samples were selected from the same geographical region as that for the dogs with diabetes, wherever possible.
Sex and neutered status were not available for all of the control dogs thus eliminating the possibility of investigating sex bias and it was not possible to assess the relatedness of affected dogs as UK Kennel Club registration numbers were not available for the majority of dogs investigated. Allelic association was conducted in a breed-by-breed manner.
DNA was extracted from residual EDTA blood samples using either a standard phenol: chloroform method or a Qiagen QIAamp DNA Blood Midi Kit in accordance with the manufacturer’s instructions. DNA quality (A260:280) and concentration were measured using a NanoDrop ( http://www.nanodrop.com/). All samples had a 260:280 ratio between 1.6 and 1.9 were diluted to a final concentration of 5 ng/μl for SNP genotyping.
Candidate gene and SNP selection
Genes and SNPs used in the study and type of human monogenic diabetes that has been associated with the gene
Type of monogenic diabetes in humans
Sulfonylurea receptor 1
B lymphoid tyrosine kinase
Carboxyl ester lipase
MODY 8 (with exocrine dysfunction)
PNDM (with epiphyseal dysplasia)
initiation factor 2a kinase
Forkhead box P3
PNDM (X-linked with immune-dysregulation, polyendocrinopathy, enteropathy)
Hepatocyte nuclear factor 1a
Hepatocyte nuclear factor 1b
MODY 5 (also with renal dysfunction, genital malformations) and PNDM
Hepatocyte nuclear factor 4a
Kruppel-like factor 11
Transfer RNA for protein
Mitochondrial diabetes (maternally transmitted with deafness)
Paired box 4
MODY 4, PNDM (with pancreatic agenesis)
Insulin promoter factor 1
PNDM (with pancreatic and cerebellar agenesis)
transcription factor 1a
Regulatory factor X6
PNDM (with hypoplastic pancreas and gall bladder, intestinal atresia)
PNDM (with diabetes insipidus, optic atrophy, deafness)
Zinc finger protein 57
Pleiomorphic adenoma gene-like 1
Primers and probes were designed using Sequenom Assay Design software Version 3, and synthesised by Sigma-Aldrich (Poole, UK). Primers were diluted to 100 μM and plexes pooled to contain 500 nm of each forward and reverse primer. Probes were diluted to 400 μM and probe pools were split into four tiers dependent upon mass. Probe pools were split into four equal tiers containing 26 μl, 35 μl, 43 μl and 52 μl of probe (low to high mass), in a final volume of 1.5 ml.
PCR reactions contained 20 ng DNA plated into a 384 well plate. PCRs were performed in 5 μl volumes using an ABI 9700 cycler (384 well). Reactions contained 0.625 μl of 10× PCR buffer (with 20 mM MgCl2, Roche), 0.2 μl of MgCl2 (25 mM), 0.25μl of dNTPs (10 mM), 100 nM of forward and reverse primer plex, 0.1 μl FastStart Taq (5 U/μl, Roche) and were amplified as follows: 95°C for 5 minutes; 40 cycles of 95°C for 20 seconds, 56°C for 30 seconds, 72°C for 1 minute; 72°C for 3 minutes. Following PCR, reactions were treated with 0.3 U/μl shrimp alkaline phosphatase (SAP) to dephosphorylate remaining dNTPs. Reactions were incubated at 37°C for 40 minutes, and denatured at 85°C for 5 minutes. iPLEX primer extension was carried out using an ABI 9700 PCR engine. Reactions contained 0.22× iPLEX buffer, 1x iPLEX termination mix, primers adjusted for concentration using a four tier method (0.625 μM, 0.83 μM, 1.04 μM, and 1.25 μM) and 1× iPLEX enzyme, and were amplified as follows: 94°C for 30 seconds, 40 cycles of 94°C for 5 seconds, 5 cycles of 52°C for 5 seconds, 80°C for 5 seconds, and a final extension of 72°C for 3 minutes. Samples were diluted with 20 μl water and desalted using 6 mg resin before being centrifuged for 5 minutes at 4,000 rpm and spotted onto a SpectroCHIP using a Sequenom mass array nanodispenser (Samsung).
Allelic association analyses
Association analyses and quality checks were carried out using PLINK . Hardy-Weinberg equilibrium (HWE) was checked for each breed control group and call rates were determined for cases and controls for each breed, independently. SNPs in which the control population was out of HWE and/or the call rate was below 90% were excluded from the analyses. Samples were excluded if the call rate was below 90%. Permutation testing and Bonferroni correction were applied to raw p values and SNPs were deemed statistically significant if p corrected <0.05.
Markers showing allelic association were also tested for a genotype association.
The UK Canine Diabetes Register and Archive has been supported by the Kennel Club Charitable Trust, Petsavers, the European Commission (FP7-LUPA, GA-201370; www.eurolupa.org) and MSD Animal Health. We are grateful to the UK Animal DNA Archive for Companion animals for providing the DNA for many of the samples. We would also like to thank the owners of dogs with diabetes and control dogs, who gave permission for their dogs to participate in this study.
- Mattheeuws D, Rottiers R, Kaneko JJ, Vermeulen A: Diabetes mellitus in dogs: relationship of obesity to glucose tolerance and insulin response. Am J Vet Res 1984,45(1):98–103.PubMed
- Davison LJ, Herrtage ME, Catchpole B: Study of 253 dogs in the United Kingdom with diabetes mellitus. Vet Rec 2005,156(15):467–471.PubMedView Article
- Davison LJ, Ristic JM, Herrtage ME, Ramsey IK, Catchpole B: Anti-insulin antibodies in dogs with naturally occurring diabetes mellitus. Vet Immunol Immunopathol 2003,91(1):53–60.PubMedView Article
- Catchpole B, Kennedy LJ, Davison LJ, Ollier WE: Canine diabetes mellitus: from phenotype to genotype. J Small Anim Pract 2008,49(1):4–10.PubMed
- Papa K, Mathe A, Bonyi-Toth Z, Sterczer A, Psader R, Hetyey C, Vajdovich P, Voros K: Occurrence, clinical features and outcome of canine pancreatitis (80 cases). Acta Vet Hung 2011,59(1):37.PubMedView Article
- Watson PJ, Archer J, Roulois AJ, Scase TJ, Herrtage ME: Observational study of 14 cases of chronic pancreatitis in dogs. Vet Rec 2010,167(25):968–976.PubMedView Article
- Davison LJ, Weenink SM, Christie MR, Herrtage ME, Catchpole B: Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. Vet Immunol Immunopathol 2008,126(1–2):83–90.PubMedView Article
- Fleeman LM, Rand JS: Management of canine diabetes. Vet Clin North Am Small Anim Pract 2001,31(5):855–880.PubMedView Article
- Davis TM: Ethnic diversity in type 2 diabetes. Diabet Med 2008,25(2):52–56. doi:10.1111/j.1464–5491.2008.02499.x., pp. 52–56PubMedView Article
- Marmor M, Willeberg P, Glickman LT, Priester WA, Cypess RH, Hurvitz AI: Epizootiologic patterns of diabetes mellitus in dogs. Am J Vet Res 1982,43(3):465–470.PubMed
- Hess RS, Kass PH, Ward CR: Breed distribution of dogs with diabetes mellitus admitted to a tertiary care facility. J Am Vet Med Assoc 2000, 216: 1414–1417.PubMedView Article
- Kramer JW, Klaassen JK, Baskin DG, Prieur DJ, Rantanen NW, Robinette JD, Graber WR, Rashti L: Inheritance of diabetes mellitus in Keeshond dogs. Am J Vet Res 1988,49(3):428–431.PubMed
- Fall T, Hamlin HH, Hedhammar A, Kampe O, Egenvall A: Diabetes mellitus in a population of 180,000 insured dogs: incidence, survival, and breed distribution. J Vet Intern Med 2007,21(6):1209–1216.PubMedView Article
- Chen R, Corona E, Sikora M, Dudley JT, Morgan AA, Moreno-Estrada A, Nilsen GB, Ruau D, Lincoln SE, Bustamante CD, Butte AJ: Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases. PLoS Genet 2012,8(4):e1002621.PubMed CentralPubMedView Article
- Steck AK, Bugawan TL, Valdes AM, Emery LM, Blair A, Norris JM, Redondo MJ, Babu SR, Erlich HA, Eisenbarth GS, Rewers MJ: Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes 2005,54(8):2482–2486.PubMedView Article
- Yamagata K, Furuta H, Oda N, Kaisaki PJ, Menzel S, Cox NJ, Fajans SS, Signorini S, Stoffel M, Bell GI: Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature 1996,384(6608):458–460.PubMedView Article
- Cao H, Shorey S, Robinson J, Metzger DL, Stewart L, Cummings E, Hegele RA: GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY). Hum Mutat 2002,20(6):478–479.PubMedView Article
- Pruhova S, Ek J, Lebl J, Sumnik Z, Saudek F, Andel M, Pedersen O, Hansen T: Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha. Diabetologia 2003,46(2):291–295.PubMed
- Ellard S: Hepatocyte nuclear factor 1 alpha (HNF-1 alpha) mutations in maturity-onset diabetes of the young. Hum Mutat 2000,16(5):377–385.PubMedView Article
- Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI: Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996,384(no. 6608):455–458.PubMedView Article
- Stoffers DA, Ferrer J, Clarke WL, Habener JF: Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997,17(2):138–139.PubMedView Article
- Wang L, Coffinier C, Thomas MK, Gresh L, Eddu G, Manor T, Levitsky LL, Yaniv M, Rhoads DB: Selective deletion of the Hnf1beta (MODY5) gene in beta-cells leads to altered gene expression and defective insulin release. Endocrinology 2004,145(8):3941–3949.PubMedView Article
- Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B, Shepherd MH, Hussain K, Kapoor RR, Malecki M, MacDonald MJ, Stoy J, Steiner DF, Philipson LH, Bell GI, Hattersley AT, Ellard S: Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008,57(4):1034–1042.PubMedView Article
- Stoy J, Steiner DF, Park SY, Ye H, Philipson LH, Bell GI: Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord 2010,11(3):205–215.PubMed CentralPubMedView Article
- Hussain K: Mutations in pancreatic ss-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus. Rev Endocr Metab Disord 2010,11(3):179–183.PubMedView Article
- Catchpole B, Adams JP, Holder AL, Short AD, Ollier WE, Kennedy LJ: Genetics of canine diabetes mellitus: are the diabetes susceptibility genes identified in humans involved in breed susceptibility to diabetes mellitus in dogs? Vet J 2013,195(2):139–147.PubMedView Article
- Atkins CE, LeCompte PM, Chin HP, Hill JR, Ownby CL, Brownfield MS: Morphologic and immunocytochemical study of young dogs with diabetes mellitus associated with pancreatic islet hypoplasia. Am J Vet Res 1988,49(9):1577–1581.PubMed
- Ramirez-Soriano A, Lao O, Soldevila M, Calafell F, Bertranpetit J, Comas D: Haplotype tagging efficiency in worldwide populations in CTLA4 gene. Genes Immun 2005,6(8):646–657.PubMed
- Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ III, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, DeJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, et al.: Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005,438(no. 7069):803–819.PubMedView Article
- Ostrander EA, Comstock KE: The domestic dog genome. Curr Biol 2004,14(3):R98-R99.PubMedView Article
- Sutter NB, Ostrander EA: Dog star rising: the canine genetic system. Nat Rev Genet 2004,5(12):900–910.PubMedView Article
- Karlsson EK, Lindblad-Toh K: Leader of the pack: gene mapping in dogs and other model organisms. Nat Rev Genet 2008,9(9):713–725.PubMedView Article
- Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, Edghill EL, Mackay DJ, Proks P, Shimomura K, Haberland H, Carson DJ, Shield JP, Hattersley AT, Ashcroft FM: Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 2007,81(2):375–382.PubMed CentralPubMedView Article
- Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Guilar-Bryan L, Vaxillaire M, Froguel P: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006,355(5):456–466.PubMedView Article
- Bonnefond A, Yengo L, Philippe J, Dechaume A, Ezzidi I, Vaillant E, Gjesing AP, Andersson EA, Czernichow S, Hercberg S, Hadjadj S, Charpentier G, Lantieri O, Balkau B, Marre M, Pedersen O, Hansen T, Froguel P, Vaxillaire M: Reassessment of the putative role of BLK-p.A71T loss-of-function mutation in MODY and type 2 diabetes. Diabetologia 2013,56(3):492–496.PubMedView Article
- Borowiec M, Liew CW, Thompson R, Boonyasrisawat W, Hu J, Mlynarski WM, El Khattabi I, Kim SH, Marselli L, Rich SS, Krolewski AS, Bonner-Weir S, Sharma A, Sale M, Mychaleckyj JC, Kulkarni RN, Doria A: Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci U S A 2009,106(34):14460–14465.PubMed CentralPubMedView Article
- Torsvik J, Johansson S, Johansen A, Ek J, Minton J, Raeder H, Ellard S, Hattersley A, Pedersen O, Hansen T, Molven A, Njolstad PR: Mutations in the VNTR of the carboxyl-ester lipase gene (CEL) are a rare cause of monogenic diabetes. Hum Genet 2010,127(1):55–64.PubMedView Article
- Raeder H, Johansson S, Holm PI, Haldorsen IS, Mas E, Sbarra V, Nermoen I, Eide SA, Grevle L, Bjorkhaug L, Sagen JV, Aksnes L, Sovik O, Lombardo D, Molven A, Njolstad PR: Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet 2006,38(1):54–62.PubMedView Article
- Raeder H, Vesterhus M, El OA, Paulo JA, McAllister FE, Liew CW, Hu J, Kawamori D, Molven A, Gygi SP, Njolstad PR, Kahn CR, Kulkarni RN: Absence of diabetes and pancreatic exocrine dysfunction in a transgenic model of carboxyl-ester lipase-MODY (maturity-onset diabetes of the young). PLoS ONE 2013,no. 4(4):e60229.View Article
- Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C: EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000,25(4):406–409.PubMedView Article
- Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001,27(1):20–21.PubMedView Article
- Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001,27(1):18–20.PubMedView Article
- Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S: Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat 2013,34(5):669–685.PubMedView Article
- Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI: Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997,17(4):384–385.PubMedView Article
- Bulman MP, Dronsfield MJ, Frayling T, Appleton M, Bain SC, Ellard S, Hattersley AT: A missense mutation in the hepatocyte nuclear factor 4 alpha gene in a UK pedigree with maturity-onset diabetes of the young. Diabetologia 1997,40(7):859–862.PubMedView Article
- Neve B, Fernandez-Zapico ME, Shkenazi-Katalan V, Dina C, Hamid YH, Joly E, Vaillant E, Benmezroua Y, Durand E, Bakaher N, Delannoy V, Vaxillaire M, Cook T, Linga-Thie GM, Jansen H, Charles MA, Clement K, Galan P, Hercberg S, Helbecque N, Charpentier G, Prentki M, Hansen T, Pedersen O, Urrutia R, Melloul D, Froguel P: Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A 2005,102(no. 13):4807–4812.PubMed CentralPubMedView Article
- Murphy R, Turnbull DM, Walker M, Hattersley AT: Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med 2008,25(4):383–399.PubMedView Article
- van den Ouweland JM, Lemkes HH, Ruitenbeek W, Sandkuijl LA, de Vijlder MF, Struyvenberg PA, van de Kamp JJ, Maassen JA: Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1992,1(5):368–371.PubMedView Article
- Plengvidhya N, Kooptiwut S, Songtawee N, Doi A, Furuta H, Nishi M, Nanjo K, Tantibhedhyangkul W, Boonyasrisawat W, Yenchitsomanus PT, Doria A, Banchuin N: PAX4 mutations in Thais with maturity onset diabetes of the young. J Clin Endocrinol Metab 2007,92(7):2821–2826.PubMedView Article
- De FE, Shaw-Smith C, Flanagan SE, Edghill EL, Wolf J, Otte V, Ebinger F, Varthakavi P, Vasanthi T, Edvardsson S, Hattersley AT, Ellard S: Biallelic PDX1 (insulin promoter factor 1) mutations causing neonatal diabetes without exocrine pancreatic insufficiency. Diabet Med 2013,30(5):e197-e200.View Article
- Sellick GS, Barker KT, Stolte-Dijkstra I, Fleischmann C, Coleman RJ, Garrett C, Gloyn AL, Edghill EL, Hattersley AT, Wellauer PK, Goodwin G, Houlston RS: Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet 2004,36(12):1301–1305.PubMedView Article
- Smith SB, Qu HQ, Taleb N, Kishimoto NY, Scheel DW, Lu Y, Patch AM, Grabs R, Wang J, Lynn FC, Miyatsuka T, Mitchell J, Seerke R, Desir J, Vanden ES, Abramowicz M, Kacet N, Weill J, Renard ME, Gentile M, Hansen I, Dewar K, Hattersley AT, Wang R, Wilson ME, Johnson JD, Polychronakos C, German MS: Rfx6 directs islet formation and insulin production in mice and humans. Nature 2010,463(7282):775–780.PubMed CentralPubMedView Article
- Strom TM, Hortnagel K, Hofmann S, Gekeler F, Scharfe C, Rabl W, Gerbitz KD, Meitinger T: Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet 1998,7(13):2021–2028.PubMedView Article
- Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal-Mizrachi E, Mueckler M, Marshall H, Donis-Keller H, Crock P, Rogers D, Mikuni M, Kumashiro H, Higashi K, Sobue G, Oka Y, Permutt MA: A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998,20(2):143–148.PubMedView Article
- Mackay DJ, Callaway JL, Marks SM, White HE, Acerini CL, Boonen SE, Dayanikli P, Firth HV, Goodship JA, Haemers AP, Hahnemann JM, Kordonouri O, Masoud AF, Oestergaard E, Storr J, Ellard S, Hattersley AT, Robinson DO, Temple IK: Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57. Nat Genet 2008,40(8):949–951.PubMedView Article
- George Priya DC, Sudandiradoss C, Rajasekaran R, Choudhury P, Sinha P, Hota P, Batra UP, Rao S: Applications of computational algorithm tools to identify functional SNPs. Funct Integr Genomics 2008,8(4):309–316.View Article
- Short AD: The Genetics of Canine Diabetes: A Candidate Gene Study. In PhD Thesis. Manchester: University of Manchester; 2006.
- Short AD, Catchpole B, Kennedy LJ, Barnes A, Fretwell N, Jones C, Thomson W, Ollier WER: Analysis of candidate susceptibility genes in canine diabetes. J Hered 2007,98(5):518–525.PubMedView Article
- Short AD, Catchpole B, Kennedy LJ, Barnes A, Lee AC, Jones CA, Fretwell N, Ollier WE: T cell cytokine gene polymorphisms in canine diabetes mellitus. Vet Immunol Immunopathol 2008, 128: 137–146.PubMedView Article
- Short AD, Saleh NM, Catchpole B, Kennedy LJ, Barnes A, Jones CA, Fretwell N, Ollier WE: CTLA4 promoter polymorphisms are associated with canine diabetes mellitus. Tissue Antigens 2010,75(3):242–252.PubMedView Article
- Kennedy LJ, Davison LJ, Barnes A, Short AD, Fretwell N, Jones CA, Lee AC, Ollier WE, Catchpole B: Identification of susceptibility and protective major histocompatibility complex haplotypes in canine diabetes mellitus. Tissue Antigens 2006,68(6):467–476.PubMedView Article
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007,81(3):559–575.PubMed CentralPubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.